Minerva Neurosciences, Inc. NERV PHARMA
Company Overview
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of -0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +141.44% |
| 6 Months: | -45.38% |
| 3 Months: | -5.62% |
| 1 Month: | +2.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.59 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 45.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NERV Minerva Neurosciences, Inc. PHARMA | 4.37 | -0.12 | $208.66M | 0.00% | -15.79% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 0 | 41.18M | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.90M | 3.37M | 2.84M | 4.98M | 16.67M | - |
| Operating Income | -8.19M | -7.76M | -4.96M | -8.23M | -9.24M | -10.48M | -9.75M | -11.41M | -9.53M | -12.74M | -12.94M | -12.42M | -13.63M | -16.31M | -12.90M | -14.28M | -32.37M | -12.27M | 29.51M | -8.09M | -7.30M | -7.51M | -8.96M | -7.52M | -7.99M | -6.97M | -5.21M | -5.35M | -4.52M | -6.08M | -6.68M | -6.28M | -4.37M | - | -3.90M | -3.37M | -2.84M | -4.98M | -16.67M | -10.64M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.90M | -3.26M | -2.74M | -283.67M | -16.67M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.75M | -3.26M | -2.74M | -283.67M | -125.40M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -8.44M | -8.00M | -5.21M | -8.42M | -9.40M | -10.64M | -9.78M | -11.26M | 162.00K | -12.42M | -12.53M | -12.02M | -13.20M | -15.83M | -12.48M | -13.96M | -29.92M | -12.15M | 29.53M | -8.11M | -7.32M | -8.80M | -10.59M | -9.21M | -9.76M | -8.72M | -6.90M | -6.97M | -6.19M | -7.82M | -8.57M | -8.23M | 22.51M | - | -3.75M | -3.26M | -2.74M | -283.67M | -125.40M | 17.47M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.32 | -0.36 | - | - | 0.73 | -0.19 | - | - | -0.25 | -1.72 | -1.83 | -1.63 | -1.29 | -1.31 | -1.12 | -1.03 | -1.13 | -1.09 | 2.97 | - | -0.50 | -0.43 | -0.36 | -25.51 | -2.86 | -0.14 |
| R&D Expense | - | 5.37M | 2.71M | 5.85M | - | 7.61M | 7.14M | 8.96M | - | 8.45M | 9.06M | 8.37M | - | 11.61M | 8.32M | 9.67M | - | 8.08M | 5.77M | 4.64M | - | 3.26M | 5.52M | 4.51M | 4.96M | 4.13M | 2.37M | 2.65M | 1.89M | 3.44M | 4.17M | 3.86M | 1.89M | - | 1.36M | 1.30M | 925.38K | - | 5.25M | 7.19M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 25.23M | 23.12M | 21.85M | 15.10M |
| Operating Income | -3.17M | -54.87M | -26.11M | -30.19M | -41.17M | -51.73M | -75.87M | 1.85M | - | -25.23M | -23.12M | -21.85M | -15.10M |
| EBITDA | - | - | - | - | - | - | - | - | - | -24.69M | -21.69M | 6.02M | -293.42M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 7.41M | 8.28M | 4.56M | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | -32.11M | -30.01M | 1.44M | -293.42M |
| Tax Provision | - | - | - | - | - | - | - | - | -1.80M | 0 | - | - | - |
| Net Income | -3.26M | -56.90M | -27.08M | -31.05M | -31.52M | -50.17M | -72.18M | 1.94M | - | -32.11M | -30.01M | 1.44M | -293.42M |
| Diluted EPS | - | - | - | - | - | - | -1.85 | 0.05 | - | -6.01 | -4.61 | 0.19 | -34.67 |
| R&D Expense | 708.49K | 42.91M | 18.53M | 20.44M | 30.26M | 34.89M | 58.12M | 22.04M | 32.04M | 14.65M | 12.71M | 11.90M | 5.76M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 29.17M | 68.45M | 82.58M | 132.94M | 183.70M | 139.14M | 77.50M | 57.63M | - | 55.09M | 56.90M | 37.14M | 97.97M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 40.16M | 42.00M | 22.27M | 83.10M |
| Cash & Equivalents | 200.31K | 1.82M | 18.55M | 14.28M | 82.98M | 26.05M | 50.23M | 21.41M | 25.36M | - | 36.09M | 40.91M | 21.36M | 82.30M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 9.00M | 16.95M | 27.26M | 26.96M | 52.10M | 48.87M | 49.72M | 4.96M | - | 75.11M | 85.36M | 62.84M | 238.72M |
| Current Liabilities | - | 1.41M | 3.51M | 5.32M | 9.69M | 6.84M | 3.61M | 6.63M | 3.16M | - | 1.38M | 3.34M | 2.84M | 2.29M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Total Equity | 19.02K | 20.18M | 51.50M | 55.32M | 105.98M | 131.60M | 90.26M | 27.78M | 52.66M | - | -20.02M | -28.46M | -25.69M | -140.75M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 5.34M | 6.99M | 6.99M | 43.27M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | 3.09M | -41.94M | -43.43M | -33.82M | - | -24.65M | -14.78M | -19.55M | -13.51M |
| Investing Cash Flow | - | - | -107.19M | 69.49M | 14.08M | 24.53M | - | -16.33K | 0 | 0 | 0 |
| Financing Cash Flow | - | - | 47.17M | -3.34M | 525.00K | 13.24M | - | -5 | 19.60M | 0 | 74.45M |
| Capital Expenditure | -3.23K | -45.61K | -52.40K | - | - | - | - | -16.33K | - | - | - |
| Free Cash Flow | - | - | 3.04M | - | - | - | - | -24.66M | -14.78M | -19.55M | -13.51M |
| Net Change in Cash | - | - | - | - | - | - | - | -24.66M | 4.82M | -19.55M | 60.94M |
| Share Buybacks | - | - | 389 | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -16.2% | -110.5% | -49.0% | -29.3% | -24.0% | -55.6% | -259.8% | 3.7% | - | 160.3% | 105.4% | -5.6% | 208.5% |
| ROCE % | -11.4% | -84.5% | -33.8% | -24.5% | -23.3% | -38.2% | -107.0% | 3.4% | - | -47.0% | -43.2% | -63.7% | -15.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Federated Hermes, Inc. | 9.78% | 4.67M | $17.09M |
| 2 | Jupiter Topco LLC | 9.19% | 4.39M | $16.05M |
| 3 | Vivo Capital, LLC | 9.05% | 4.32M | $15.82M |
| 4 | Balyasny Asset Management LP | 8.92% | 4.26M | $15.58M |
| 5 | Logos Global Management LP | 6.89% | 3.29M | $12.04M |
| 6 | Farallon Capital Management LLC | 4.95% | 2.37M | $8.66M |
| 7 | Blackrock Inc. | 4.69% | 2.24M | $8.20M |
| 8 | Ally Bridge Group (NY) LLC | 4.56% | 2.18M | $7.96M |
| 9 | Foresite Capital Management VI LLC | 4.16% | 1.99M | $7.27M |
| 10 | Vanguard Capital Management LLC | 3.96% | 1.89M | $6.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NERV
Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues | NERV Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOYlVUN1gwTHRPMVpELVJySnotdWtfRGt2V3ZwQ0UzRG1RTHFCSVF2RmhtOEtrUUpMMFZqd3h5SXpnVFQ2ZjlrcGgzRXNsWkJjVUwtc3VnblBNUnJNS0x3SGFQWlp0N3VSRHlhT3B5R01mQTNqb1FYMzZpb0F2NXVoSnQ2dTZpMXhzcHpleF…
Minerva Neurosciences (NASDAQ: NERV) COO holds 20,872 shares, 750K and 680K options - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPUGNUR0QyNWlBaHZhb2M0RXYteFlaTmliSDZaTDdTQmtpZXNub3h1dnk2VzllQlV1NkFUN0dTWHVOb2tCWE10bUlObHlyMUxoVzlKMXZoUTJfQUtnZjhaUHhnVUhpdFNhT1hsWkpwNE96Vm5IckhRWHktSnAyQUtSY3Uta1VseFUwMnVuRF…
Should I buy Minerva Neurosciences (NERV) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE5Fbjd4bEREQlkzMWtqNlEtLUwxZGFhM2VJQTQ3TmtHS0psVWRZUmRGcWpNSDJETHRXWjhMY3pjUGlUREFCSFo5LU1MVTNvRml3MmM3SlhhRWdWeDZxNHZrTkphU19hT0o0a21ZbA?oc=5" target="_blank">Should I buy Minerva …
Minerva Neurosciences Inc (NASDAQ: NERV) Share Price, NERV Stock News, NERV Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE8xdEt0eHJCcGVYMGhZNzB2TUppckhjb2kxY3lsNXBjRzEyc1VtVHplMGRxT1RaZ0NJdVh4MWhCa0sxNkNUUjkyNEJtOHcweERqbEprWm5R?oc=5" target="_blank">Minerva Neurosciences Inc (NASDAQ: NERV) Share Pric…
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway - Investing.com
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTEU3Y0FHbEtIcno4VjZHQUx2bmNNd3VST3JpQWQ5Z3dLMFlnZlNLbTBNbUxBT0NfS2VCS1RvWjJidVdBUldyU2N4OElRblV5MUYza2dNSnZZWl9NMW8tRFNSaS1XTjNBbkNWZE4wQ1h1OElTOGhUTEcyTlFMdjdCSFB1OHI1NkNmY0FWcX…
Minerva stock wins New Outperform at Citizens (NERV:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPMm5YXzRTYzA5OEl3YnJnLUZxenFtYUdYanJ4eHlNZXhFd0JNSmQ5Z29acmhjbHdhTkpYb0lKYnV2Mlc0cjUzbFhVUDl0UmpIbUZmS1VZR28yODhrYWMwM2ZOM2s3V19ZWjhMTmQxcHBaZWxIay03QVNmYUs2NHRyS0dmTVEtWUk?oc=5" …
NERV — Frequently Asked Questions
What is the current share price of Minerva Neurosciences, Inc. (NERV)?
As of 2026-09-19 21:16 PDT, Minerva Neurosciences, Inc. (NERV) trades at $4.37 on NasdaqCM. Its 52-week range is $1.80 to $8.07.
What is the market capitalisation of NERV?
Minerva Neurosciences, Inc. (NERV) has a market capitalisation of $208.66M on NasdaqCM.
What is the P/E ratio of NERV?
NERV trades at a trailing price-to-earnings (P/E) ratio of -0.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.81.
Is NERV a good stock to buy?
This page provides a data-driven analysis of Minerva Neurosciences, Inc. (NERV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.